SG/PUT/ABBVIE/180/0.1/21.03.25 Stock

DE000SU6QVQ8

Market Closed - Boerse Frankfurt Warrants 03:39:58 2024-07-11 pm EDT
1.68 ^EUR	-6.67%

Current month	+0.61%
1 month	-6.29%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ABBVIE INC.

Latest news about ABBVIE INC.

AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research and Development and Chief Scientific Officer	Jul. 11	AQ
Morgan Stanley Adjusts Price Target on AbbVie to $196 From $191	Jul. 11	MT
Redburn Atlantic Adjusts Price Target on AbbVie to $203 From $207	Jul. 10	MT
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer	Jul. 10	PR

More news

Quotes 5-day view

Date	Price	Change
24-07-11	1.64	-8.89%
24-07-10	1.8	+3.45%
24-07-09	1.74	-4.40%
24-07-08	1.82	-0.55%
24-07-05	1.83	-2.14%

Real-time Boerse Frankfurt Warrants

Last update July 11, 2024 at 03:39 pm EDT

More quotes

Static data

Product type	Warrant Plain-Vanilla
Buy / Sell	PUT
Underlying	ABBVIE INC.
Issuer	Société Générale
WKN	SU6QVQ
ISIN	DE000SU6QVQ8
Date issued	2024-01-08
Strike	180 $
Maturity	2025-03-21 (253 Days)
Parity	10 : 1
Emission price	2.35 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.63 €
Lowest since issue	1.29 €
Spread	0.03 €
Spread %	1.80%

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

More about the company